Neuronal and nonneuronal COX-2 expression confers neurotoxic and neuroprotective phenotypes in response to excitotoxin challenge

Journal of Neuroscience Research

Volumn 92, Issue 4, 2014, Pages 486-495

  An, Ying ^a   Belevych, Natalya ^a   Wang, Yufen ^a   Zhang, Hao ^a   Herschman, Harvey ^b   Chen, Qun ^a   Quan, Ning ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Inflammation; Injury; Knockout mouse

Indexed keywords

INFLAMMATION; INJURY; KNOCKOUT MOUSE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS, DIFFERENTIATION; CYCLOOXYGENASE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLYCINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; N-METHYLASPARTATE; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; NEUROTOXINS; PHOSPHOPYRUVATE HYDRATASE; TETRAZOLES;

EID: 84895067114     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23317     Document Type: Article

References (46)

1. Adams J, Collaco-Moraes Y, de Belleroche J. 1996. Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J Neurochem 66:6-13.
2. Ahmad M, Zhang Y, Liu H, Rose ME, Graham SH. 2009. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. Brain Res 1279:168-173.
3. Anrather J, Gallo EF, Kawano T, Orio M, Abe T, Gooden C, Zhou P, Iadecola C. 2011. Purinergic signaling induces cyclooxygenase-1-dependent prostanoid synthesis in microglia: roles in the outcome of excitotoxic brain injury. PLoS One 6:e25916.
4. Arikuni T, Kubota K. 1986. The organization of prefrontocaudate projections and their laminar origin in the macaque monkey: a retrograde study using HRP-gel. J Comp Neurol 244:492-510.
5. Ashok V, Dash C, Rohan TE, Sprafka JM, Terry PD. 2011. Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk. Breast 20:66-70.
6. Azari MF, Profyris C, Le Grande MR, Lopes EC, Hirst J, Petratos S, Cheema SS. 2005. Effects of intraperitoneal injection of Rofecoxib in a mouse model of ALS. Eur J Neurol 12:357-364.
7. Busija DW, Thore C, Beasley T, Bari F. 1996. Induction of cyclooxygenase-2 following anoxic stress in piglet cerebral arteries. Microcirculation 3:379-386.
8. Candelario-Jalil E. 2008. Nimesulide as a promising neuroprotectant in brain ischemia: new experimental evidences. Pharmacol Res 57:266-273.
9. Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL. 2010. Celecoxib vs. omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet 376:173-179.
10. Constien R, Forde A, Liliensiek B, Grone HJ, Nawroth P, Hammerling G, Arnold B. 2001. Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line. Genesis 30:36-44.
11. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB. 2006. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 60:22-31.
12. Dore S, Otsuka T, Mito T, Sugo N, Hand T, Wu L, Hurn PD, Traystman RJ, Andreasson K. 2003. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 54:155-162.
13. Friess SH, Naim MY, Kilbaugh TJ, Ralston J, Margulies SS. 2012. Premedication with meloxicam exacerbates intracranial haemorrhage in an immature swine model of non-impact inertial head injury. Lab Anim 46:164-166.
14. Gopez JJ, Yue H, Vasudevan R, Malik AS, Fogelsanger LN, Lewis S, Panikashvili D, Shohami E, Jansen SA, Narayan RK, Strauss KI. 2005. Cyclooxygenase-2-specific inhibitor improves functional outcomes, provides neuroprotection, and reduces inflammation in a rat model of traumatic brain injury. Neurosurgery 56:590-604.
15. Hakan T, Toklu HZ, Biber N, Ozevren H, Solakoglu S, Demirturk P, Aker FV. 2010. Effect of COX-2 inhibitor meloxicam against traumatic brain injury-induced biochemical, histopathological changes and blood-brain barrier permeability. Neurol Res 32:629-635.
16. Hara K, Kong DL, Sharp FR, Weinstein PR. 1998. Effect of selective inhibition of cyclooxygenase 2 on temporary focal cerebral ischemia in rats. Neurosci Lett 256:53-56.
17. Hardingham GE. 2009. Coupling of the NMDA receptor to neuroprotective and neurodestructive events. Biochem Soc Trans 37:1147-1160.
18. Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P. 2001. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol 101:2-8.
19. Iadecola C, Forster C, Nogawa S, Clark HB, Ross ME. 1999. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol 98:9-14.
20. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME. 2001. Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 98:1294-1299.
21. Jellinger KA. 2004. Head injury and dementia. Curr Opin Neurol 17:719-723.
22. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. 1996. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci U S A 93:2317-2321.
23. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C. 2006. Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12:225-229.
24. Kim HJ, Chung JI, Lee SH, Jung YS, Moon CH, Baik EJ. 2008. Involvement of endogenous prostaglandin F2alpha on kainic acid-induced seizure activity through FP receptor: the mechanism of proconvulsant effects of COX-2 inhibitors. Brain Res 1193:153-161.
25. Koistinaho J, Chan PH. 2000. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 25:645-651.
26. Koistinaho J, Koponen S, Chan PH. 1999. Expression of cyclooxygenase-2 mRNA after global ischemia is regulated by AMPA receptors and glucocorticoids. Stroke 30:1900-1905; discussion 1905-1906.
27. Loonstra A, Vooijs M, Beverloo HB, Allak BA, van Drunen E, Kanaar R, Berns A, Jonkers J. 2001. Growth inhibition and DNA damage induced by Cre recombinase in mammalian cells. Proc Natl Acad Sci U S A 98:9209-9214.
28. Lopez-Vales R, Garcia-Alias G, Fores J, Navarro X, Verdu E. 2004. Increased expression of cyclo-oxygenase 2 and vascular endothelial growth factor in lesioned spinal cord by transplanted olfactory ensheathing cells. J Neurotrauma 21:1031-1043.
29. Lopez-Vales R, Garcia-Alias G, Guzman-Lenis MS, Fores J, Casas C, Navarro X, Verdu E. 2006. Effects of COX-2 and iNOS inhibitors alone or in combination with olfactory ensheathing cell grafts after spinal cord injury. Spine 31:1100-1106.
30. Mangoni AA, Woodman RJ, Gilbert AL, Knights KM. 2010. Use of non-steroidal anti-inflammatory drugs and risk of ischemic and hemorrhagic stroke in the Australian veteran community. Pharmacoepidemiol Drug Saf 19:490-498.
31. Miettinen S, Fusco FR, Yrjanheikki J, Keinanen R, Hirvonen T, Roivainen R, Narhi M, Hokfelt T, Koistinaho J. 1997. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci U S A 94:6500-6505.
32. Narasimha AJ, Watanabe J, Ishikawa TO, Priceman SJ, Wu L, Herschman HR, Reddy ST. 2010. Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol 30:260-268.
33. Oka A, Takashima S. 1997. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8:1161-1164.
34. Paxinos G, Franklin KBJ. 2004. The mouse brain in stereotaxic coordinates. Amsterdam: Elsevier Academic Press.
35. Peura DA. 2002. Gastrointestinal safety and tolerability of nonselective nonsteroidal anti-inflammatory agents and cyclooxygenase-2-selective inhibitors. Cleve Clin J Med 69(Suppl 1):SI31-SI39.
36. Proescholdt MG, Chakravarty S, Foster JA, Foti SB, Briley EM, Herkenham M. 2002. Intracerebroventricular but not intravenous interleukin-1beta induces widespread vascular-mediated leukocyte infiltration and immune signal mRNA expression followed by brain-wide glial activation. Neuroscience 112:731-749.
37. Quan N, Whiteside M, Herkenham M. 1998. Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide. Brain Res 802:189-197.
38. Resnick DK, Graham SH, Dixon CE, Marion DW. 1998. Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma 15:1005-1013.
39. Sainati SMID, Tawalker SS. 2000.Results of a double blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. The 6th Internation Stockholm/Springfield Symposium on Advances in Alzheimer Therapy.
40. Schiltz JC, Sawchenko PE. 2002. Distinct brain vascular cell types manifest inducible cyclooxygenase expression as a function of the strength and nature of immune insults. J Neurosci 22:5606-5618.
41. 2 production in activated microglial cells. Glia 61:1607-1619.
42. Strauss KI. 2008. Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain. Brain Behav Immun 22:285-298.
43. Strauss KI. 2010. COX2 inhibitors for acquired brain injuries: is the time ripe? Crit Care Med 38:723-724.
44. Strauss KI, Barbe MF, Marshall RM, Raghupathi R, Mehta S, Narayan RK. 2000. Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat. J Neurotrauma 17:695-711.
45. Wu T, Wu H, Wang J. 2011. Expression and cellular localization of cyclooxygenases and prostaglandin E synthases in the hemorrhagic brain. J Neuroinflamm 8:22.
46. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. 2001. Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 57:952-956.